Objective-To determine the consequences of specific inhibition of EGFR (epidermal growth factor receptor) in myeloid cells in atherosclerosis development. Egfr lox/lox bone marrow, after 4 (−43%; P<0.05), 7 (−34%; P<0.05), and 12 weeks (−54%; P<0.001) of high-fat diet. Reduction of lesion size was associated with marked reduction in macrophage accumulation and necrotic core size. Specific deletion of Egfr in myeloid cells reduced TNF-α (tumor necrosis factor-α) and IL (interleukin)-6 production by stimulated macrophages but had no effect on IL-10 and IL-12p70 secretion. Finally, we found that myeloid deletion of Egfr limited cytoskeletal rearrangements and also lipid uptake by macrophages through a downregulation of the scavenger receptor CD36 (cluster of differentiation 36). Conclusions-Gene deletion of Egfr in myeloid cells limits IL-6 and TNF-α production, lipid uptake, and consecutively reduces atherosclerosis development. Visual Overview-An online visual overview is available for this article. Figure IV in the online-only Data Supplement). As shown in Figure 1A , Egfr deficiency in myeloid cells led to a 43% decrease in atherosclerotic lesion size in the aortic sinus compared with controls (16±6×10 3 μm 2 versus 28±6×10 3 μm 2 ; P<0.05). The reduction of atherosclerosis was confirmed after 7 (−34%; P<0.05) and 12 weeks (−54%; P<0.001) of high-fat diet. Plasma cholesterol levels were comparable between the groups of mice ( Figure 1B) .
A therosclerosis is a Western lifestyle-associated inflammatory disease of the arterial wall responsible for ischemic cardiovascular diseases and stroke. 1 There is a large body of human and experimental evidences showing that innate immunity plays a crucial role in atherosclerosis development and complications. Monocyte-derived macrophages of the intima internalize and are activated by a broad range of molecules and particles bearing damage-associated molecular patterns (eg, oxidized low-density lipoprotein [oxLDL] ) and ultimately are transformed into proinflammatory foam cells. Macrophage maturation, activation, and proliferation are necessary steps for atherosclerosis and are associated with upregulation of pattern recognition receptors for innate immunity, including scavenger receptors (SR-A and CD36 [cluster of differentiation 36]) and TLR (toll-like receptors). [2] [3] [4] Modulating monocyte/macrophage pathogenic function could represent an interesting therapeutic approach to limit atherosclerosis development and complications and to stop the burden of cardiovascular diseases.
The EGFR (epidermal growth factor receptor) is a prominent member of the receptor tyrosine kinase family. 5 EGFR and its ligands have been detected in atherosclerotic plaques of mice, 6 rabbits, monkeys, 7 and humans, [8] [9] [10] colocalizing with vascular smooth muscle cells and macrophages. EGFR phosphorylation has been documented in aortas of atheroprone Apoe −/− mice under a high-fat diet, and repetitive administration of AG-1478-a tyrosine kinase inhibitor specific for EGFR-reduced atherosclerosis in Apoe −/− mice. 11 However, because EGFR is expressed by vascular (endothelial and smooth muscle), myeloid, and T cells, the atheroprotective effects of tyrosine kinase inhibitor cannot be directly ascribed to the modulation of a specific cell population, in particular, monocytes/macrophages. To investigate the specific in vivo consequences of EGFR blockade in myeloid cell function, we generated a cell-specific deletion of Egfr and performed bone marrow transplantation experiments in irradiated Ldlr −/− mice.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
First of all, we searched for EGFR expression in plaques of Ldlr −/− mice-an atheroprone model routinely used for bone marrow transplantation experiments. In adult males, after 4 weeks of high-fat diet, EGFR was expressed in atherosclerotic lesions and colocalized with MOMA (monocyte-macrophage marker)-2+ macrophages. After 8 weeks of high-fat diet, in more advanced lesions, EGFR was mainly expressed around the lipid-rich necrotic area and colocalized with macrophages, although not exclusively ( Figure I in Plaque composition was analyzed in advanced lesions of chimeric Ldlr −/− mice after 12 weeks of high-fat diet. We found a decrease in both macrophage accumulation ( Figure 1C ) and necrotic core area ( Figure 1D -cultured macrophages after stimulation with oxLDL ( Figure 2C) . A reduction of CD36 protein was further confirmed by flow cytometry ( Figure 2D ). Pharmacological inhibition of EGFR using AG-1478 reduced oxLDL endocytosis in C57Bl6 control macrophages but had no effect on lipid uptake in Cd36 −/− cells suggesting that EGFR controls lipid uptake through the regulation of CD36 expression ( Figure 2E ). Finally, to evaluate the in vivo relevance of our data, we stained and quantified CD36 protein expression in plaques from chimeric Ldlr −/− mice. CD36 was detected in atherosclerotic plaques and colocalized with MOMA (monocyte-macrophage marker)-2 ( Figure X in the online-only Data Supplement). We found a profound decrease of CD36 staining in atherosclerotic plaques of chimeric Ldlr −/− mice retransplanted with LysM Cre+ Egfr lox/lox bone marrow cells ( Figure 2F ; Figure X in the online-only Data Supplement). As EGFR could interact with focal adhesion kinase 14 and CD36 is involved in cell migration, 15 we hypothesized that the atheroprotection induced by EGFR deficiency in myeloid cells could also be, in part, because of impairment of cytoskeleton rearrangements. In vitro, we found that Egfr deficiency limited monocyte adhesion to serum-coated coverslips and also limited macrophage spreading and actin polymerization when exposed to oxLDL ( Figure XI in the online-only Data Supplement). 
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Discussion
In this study, we showed that selective deletion of Egfr in myeloid cells reduced atherosclerosis development, limiting both lipid uptake and the inflammatory response.
Our study extends previous findings by highlighting the role of EGFR engagement on the inflammatory response of macrophages in the context of atherosclerosis. 11 Genetic deficiency of Egfr in myeloid cells modulated the systemic innate inflammatory response as illustrated by the reduction of proatherogenic TNF-α production by both splenocytes and macrophages after TLR4 agonist stimulation. 3, 16 Our results are consistent with the recent study by Wang et al 11 who reported a reduction of TNF-α and IL-6 production by OxLDL-stimulated macrophages after incubation with 2 different pharmacological EGFR inhibitors.
Given the strong reduction of the area of aortic oil red O staining in the absence of myeloid EGFR, we investigated the role of EGFR in macrophage foam cell formation and found a marked reduction of oxLDL uptake and lipid accumulation in Egfr-deficient macrophages. Among the major receptors that govern foam cell formation in macrophages (ie, MSR1 [macrophage scavenger receptor 1] and CD36), Egfr deletion selectively altered the expression of CD36 both at the gene and cell surface protein expression levels and both in vitro and within atherosclerotic plaque macrophages in vivo. Our results are in agreement with previous in vitro work that showed reduced lipid uptake by both mouse 11 and human 17 macrophages treated with an EGFR tyrosine kinase inhibitor. In addition, we found that AG-1478 had no effect on lipid uptake in Cd36 −/− macrophages suggesting that CD36 is the main regulatory mechanism of lipid uptake driven by the EGFR pathway. We did not investigate downstream pathways, but we speculate that PPAR-γ (peroxisome proliferator-activated receptor-γ) might be involved given its major impact on CD36 expression and its regulation by the EGFR pathway. 18 EGFR is also expressed by polymorphonuclear cells, 19 and we cannot exclude a contribution of neutrophils to the vascular phenotype observed in chimeric Ldlr −/− /LysM Cre+ Egfr lox/ lox . However, such a contribution is probably minor because previous studies that used anti-GR1 depleting strategy reported a proatherogenic role of neutrophils at early stages of atherosclerosis but no significant effect in advanced plaques. 20 Here, we reported that myeloid EGFR deficiency was protective at both early and late stages of atherosclerosis development.
Conclusion
Selective deletion of EGFR in myeloid cells reduced atherosclerosis and plaque inflammation. Our findings suggest that targeting of EGFR pathway could be an interesting therapeutic strategy to limit plaque growth and promote plaque stability. 
